PHATHOM PHARMACEUTICALS, INC. Inventory Write-down
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Inventory Write-down of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2026-06-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2025-12-31 was -$539.00K, a 549.17% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. inventory write-down for fiscal 2025 was $280.00K, a 66.51% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. inventory write-down for fiscal 2024 was $836.00K.
- PHATHOM PHARMACEUTICALS, INC. inventory write-down for fiscal 2023 was $0.00.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 | -$539.00K derived: sum of 3 quarters · filed 2026-07-30 | -$539.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | -$539.00K derived: sum of 2 quarters · filed 2026-04-30 | -$539.00K derived: sum of 3 quarters · filed 2026-04-30 | -$619.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$539.00K derived: sum of 2 quarters · filed 2026-02-26 | -$619.00K derived: sum of 3 quarters · filed 2026-07-30 | $280.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$80.00K derived: sum of 2 quarters · filed 2026-07-30 | $819.00K 10-Q · filed 2025-10-30 | $939.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $819.00K 10-Q · filed 2026-07-30 | $939.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.41M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $899.00K 10-Q · filed 2026-04-30 | $1.02M derived: sum of 2 quarters · filed 2026-04-30 | $1.49M derived: sum of 3 quarters · filed 2026-04-30 | $1.74M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $593.00K derived: sum of 2 quarters · filed 2026-02-26 | $836.00K derived: sum of 3 quarters · filed 2026-02-26 | $836.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $473.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $716.00K derived: sum of 2 quarters · filed 2025-10-30 | $716.00K 10-Q · filed 2025-10-30 | $716.00K derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $243.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $243.00K 10-Q · filed 2025-08-07 | $243.00K derived: sum of 3 quarters · filed 2025-08-07 | $243.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2025-05-01 | $0.00 derived: sum of 3 quarters · filed 2025-05-01 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |